Your browser doesn't support javascript.
loading
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study.
Brogna, Claudia; Pane, Marika; Coratti, Giorgia; D'Amico, Adele; Pegoraro, Elena; Bello, Luca; Sansone, Valeria Ada Maria; Albamonte, Emilio; Messina, Sonia; Pini, Antonella; D'Angelo, Maria Grazia; Bruno, Claudio; Mongini, Tiziana; Ricci, Federica Silvia; Berardinelli, Angela; Battini, Roberta; Masson, Riccardo; Bertini, Enrico Silvio; Politano, Luisa; Mercuri, Eugenio.
Afiliação
  • Brogna C; Pediatric Neurology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Pane M; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Coratti G; Pediatric Neurology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • D'Amico A; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Pegoraro E; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Bello L; Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Sansone VAM; Department of Neurosciences, University of Padua, 35128 Padua, Italy.
  • Albamonte E; Department of Neurosciences, University of Padua, 35128 Padua, Italy.
  • Messina S; The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, 20162 Milan, Italy.
  • Pini A; The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, 20162 Milan, Italy.
  • D'Angelo MG; Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
  • Bruno C; Neuromuscular Pediatric Unit, IRRCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
  • Mongini T; NeuroMuscular Unit IRCCS Eugenio Medea, Bosisio Parini, 23842 Lecco, Italy.
  • Ricci FS; Center of Translational and Experimental Myology and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Istituto Giannina Gaslini and University of Genoa, 16132 Genoa, Italy.
  • Berardinelli A; Neuromuscular Center, AOU Città della Salute e della Scienza, University of Torino, 10100 Turin, Italy.
  • Battini R; Neuromuscular Center, AOU Città della Salute e della Scienza, University of Torino, 10100 Turin, Italy.
  • Masson R; National Neurological Institute C. Mondino Foundation, IRCCS, 27100 Pavia, Italy.
  • Bertini ES; Department of Developmental Neuroscience, IRCCS Stella Maris, 56018 Pisa, Italy.
  • Politano L; Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
  • Mercuri E; Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
  • Italian Dmd Group; Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Children (Basel) ; 10(4)2023 Apr 19.
Article em En | MEDLINE | ID: mdl-37189996
ABSTRACT

INTRODUCTION:

The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne Muscular Dystrophy (DMD) to study longitudinal functional changes of motor upper limb function in ambulant and non-ambulant patients. The aim of this study was to evaluate changes in upper limb functions in patients carrying mutations amenable to skipping exons 44, 45, 51 and 53.

METHODS:

All DMD patients were assessed using the PUL 2.0 for at least 2 years, focusing on 24-month paired visits in those with mutations eligible for skipping exons 44, 45, 51 and 53.

RESULTS:

285 paired assessments were available. The mean total PUL 2.0 12-month change was -0.67 (2.80), -1.15 (3.98), -1.46 (3.37) and -1.95 (4.04) in patients carrying mutations amenable to skipping exon 44, 45, 51 and 53, respectively. The mean total PUL 2.0 24-month change was -1.47 (3.73), -2.78 (5.86), -2.95 (4.56) and -4.53 (6.13) in patients amenable to skipping exon 44, 45, 51 and 53, respectively. The difference in PUL 2.0 mean changes among the type of exon skip class for the total score was not significant at 12 months but was significant at 24 months for the total score (p < 0.001), the shoulder (p = 0.01) and the elbow domain (p < 0.001), with patients amenable to skipping exon 44 having smaller changes compared to those amenable to skipping exon 53. There was no difference within ambulant or non-ambulant cohorts when subdivided by exon skip class for the total and subdomains score (p > 0.05).

CONCLUSIONS:

Our results expand the information on upper limb function changes detected by the PUL 2.0 in a relatively large group of DMD patients with distinct exon-skipping classes. This information can be of help when designing clinical trials or in the interpretation of the real world data including non-ambulant patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Children (Basel) Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Children (Basel) Ano de publicação: 2023 Tipo de documento: Article